Quotient Ltd (QTNT): Jeremy Stackawitz , President of Quotient Ltd sold 15,000 shares on Jun 9, 2016. The Insider selling transaction was reported by the company on Jun 10, 2016 to the Securities and Exchange Commission. The shares were sold at $10.00 per share for a total value of $150,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 6, 2016, Stephen Unger (Chief Financial Officer) sold 14,484 shares at $9.99 per share price.On Feb 11, 2016, Zubeen Shroff (director 10% owner) purchased 222,222 shares at $9.00 per share price.Also, On Jun 4, 2015, Sarah A Oconnor (director) purchased 10,000 shares at $15.50 per share price.On Mar 10, 2015, D J Paul E Cowan (director officer 10% owner ) sold 75,000 shares at $16.80 per share price.
Quotient Ltd: On Thursday, Jun 9, 2016 heightened volatility was witnessed in Quotient Ltd which led to swings in the share price. The shares opened for trading at $9.82 and hit $10.265 on the upside , eventually ending the session at $10.1, with a gain of 4.12% or 0.3999 points. The heightened volatility saw the trading volume jump to 1,96,080 shares. The 52-week high of the share price is $19.9499 and the company has a market cap of $257 M . The 52-week low of the share price is at $6.5.
Quotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood which includes antigen typing and antibody identification. Serological disease screening involves the screening of donor blood for unwanted pathogens. The Company is engaged in the development manufacturing and commercialization of conventional reagent products for blood grouping. The Company also undertakes product development projects for its original equipment manufacturer (OEM) customers. The Company develops manufactures and commercializes the products including Antisera products Reagent Red Blood Cells Whole Blood Controls and Ancillary products. The Company is developing MosaiQ to characterize donor and patient blood and serologically screen donor blood for specific viruses.